XJPX
7096
Market cap51mUSD
Dec 05, Last price
775.00JPY
1D
0.13%
1Q
-17.90%
IPO
-60.46%
Name
StemCell Institute
Chart & Performance
P/E
20.58
P/S
2.96
EPS
37.65
Div Yield, %
3.23%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
9.84%
Revenues
2.68b
+7.98%
Net income
386m
+24.06%
CFO
468m
+39.76%
Dividend
Sep 27, 202425 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||